Ysios Capital exits Memo Therapeutics with acquisition by Ipsen

Ysios Capital has announced its exit from the Swiss biotech Memo Therapeutics, specializing in antibodies against infections and cancer. Memo Therapeutics will be acquired by pharmaceutical giant Ipsen in a deal that could exceed 700 million.